Imeros (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions needed for depolarisation. This reversible blockade stops nerve impulse transmission, resulting in localized numbness in the area where the drug is injected.

The appropriate dose of Imeros is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical setting. Dosage is individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for mepivacaine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the Imeros product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mepivacaine offers a rapid onset and intermediate duration of action, similar to lidocaine but with slightly less vasodilatory effect. Compared with bupivacaine, it has a shorter duration and lower cardiotoxic potential, making it suitable for shorter procedures where quick recovery is desired.

Imeros should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not freeze the product. Ensure the vial is kept upright and avoid exposure to extreme temperatures during transport.

Imeros is administered by a qualified professional via infiltration, peripheral nerve block, or intra‑oral injection. The drug is injected directly into the target tissue or around the nerve sheath using aseptic technique, with dosage adjusted to the specific clinical situation.

Serious risks include allergic reactions (rash, swelling, anaphylaxis), central nervous system toxicity such as seizures, and cardiovascular events like arrhythmias or severe hypotension. Immediate medical attention is required if any of these symptoms occur.

Imeros should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe hepatic impairment, or individuals with certain cardiac conduction disorders. It is also contraindicated when used in conjunction with drugs that may cause severe toxicity, such as class I anti‑arrhythmics.